Inlyta and Tracleer (Bosentan Tablets)
Determining the interaction of Inlyta and Tracleer (Bosentan Tablets) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Bosentan may significantly reduce the blood levels of axitinib, which may make the medication less effective in treating your condition. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme. In a study of 40 healthy, nonsmoking, male volunteers, administration of a single 5 mg dose of axitinib on day 8 of treatment with the potent CYP450 3A4 inducer rifampin (600 mg/day for 9 days) resulted in a 71% decrease in mean axitinib peak plasma concentration (Cmax) and 79% decrease in mean systemic exposure. The extent to which other, less potent inducers of CYP450 3A4 may interact with axitinib is unknown.
MANAGEMENT: Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.
- Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70
- "Product Information. Inlyta (axitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
Generic Name: bosentan
Brand name: Tracleer
Synonyms: Tracleer
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Inlyta-Tradjenta
- Inlyta-Tramacet
- Inlyta-Tramadol
- Inlyta-Tramadol and acetaminophen
- Inlyta-Tramadol Capsules
- Inlyta-Tramadol ER
- Tracleer (Bosentan Tablets)-Innerclean
- Tracleer (Bosentan Tablets)-Innofem
- Tracleer (Bosentan Tablets)-Innohep
- Tracleer (Bosentan Tablets)-InnoPran XL
- Tracleer (Bosentan Tablets)-Inomax
- Tracleer (Bosentan Tablets)-INOmax inhalation gas